Elizabeth V. Rodriguez on July 27, 2026 10:36 pm Interesting update on Elephant Gun Vs Human. Curious how the grades will trend next quarter. Reply
John C. Brown on July 27, 2026 10:36 pm Exploration results look promising, but permitting will be the key risk. Reply
Jennifer Jones on July 27, 2026 10:37 pm Silver leverage is strong here; beta cuts both ways though. Reply
Mary Brown on July 27, 2026 10:37 pm Exploration results look promising, but permitting will be the key risk. Reply
Olivia Garcia on July 27, 2026 10:39 pm The cost guidance is better than expected. If they deliver, the stock could rerate. Reply
Liam Q. Davis on July 27, 2026 10:41 pm Uranium names keep pushing higher—supply still tight into 2026. Reply
Patricia Thompson on July 27, 2026 10:43 pm Interesting update on Elephant Gun Vs Human. Curious how the grades will trend next quarter. Reply
Olivia Miller on July 27, 2026 10:44 pm Nice to see insider buying—usually a good signal in this space. Reply
Linda Thompson on July 27, 2026 10:44 pm Nice to see insider buying—usually a good signal in this space. Reply
Amelia Martin on July 27, 2026 10:46 pm The cost guidance is better than expected. If they deliver, the stock could rerate. Reply
John S. Moore on July 27, 2026 10:46 pm The cost guidance is better than expected. If they deliver, the stock could rerate. Reply
Isabella Martinez on July 27, 2026 10:48 pm Exploration results look promising, but permitting will be the key risk. Reply
William Brown on July 27, 2026 10:48 pm Uranium names keep pushing higher—supply still tight into 2026. Reply
Elijah Martin on July 27, 2026 10:50 pm I like the balance sheet here—less leverage than peers. Reply
By Garand Thumb
By Garand Thumb
By Garand Thumb
29 Comments
Interesting update on Elephant Gun Vs Human. Curious how the grades will trend next quarter.
Exploration results look promising, but permitting will be the key risk.
Silver leverage is strong here; beta cuts both ways though.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Exploration results look promising, but permitting will be the key risk.
Good point. Watching costs and grades closely.
The cost guidance is better than expected. If they deliver, the stock could rerate.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Uranium names keep pushing higher—supply still tight into 2026.
I like the balance sheet here—less leverage than peers.
Interesting update on Elephant Gun Vs Human. Curious how the grades will trend next quarter.
Nice to see insider buying—usually a good signal in this space.
Good point. Watching costs and grades closely.
Nice to see insider buying—usually a good signal in this space.
The cost guidance is better than expected. If they deliver, the stock could rerate.
The cost guidance is better than expected. If they deliver, the stock could rerate.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Exploration results look promising, but permitting will be the key risk.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Uranium names keep pushing higher—supply still tight into 2026.
Good point. Watching costs and grades closely.
If AISC keeps dropping, this becomes investable for me.
Good point. Watching costs and grades closely.
I like the balance sheet here—less leverage than peers.
Good point. Watching costs and grades closely.